Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Successful Completion of Phase I/IIa Clinical Study of VAC-3S Immunotherapeutic Vaccine

Published: Monday, December 03, 2012
Last Updated: Monday, December 03, 2012
Bookmark and Share
Interim results of the phase I/IIa clinical study revealed a good safety and tolerability profile for the VAC-3S immunotherapeutic vaccine, which was the primary endpoint of the study performed in two AP-HP reference clinical centers in Paris, France, at Pitié Salpêtrière and Cochin Hospitals.

InnaVirVax has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

A phase I/IIa dose escalation study was performed in 24 patients living with HIV whose CD4 T-lymphocyte levels were higher than 200/mm3 and who were under antiretroviral therapy [ART].

The treatment was administered in 3 injections at 4-week intervals. The primary endpoint of this study was to assess the safety and tolerability of VAC-3S, four weeks after the third injection.

Secondary endpoints included an evaluation of the immune response, the long-term safety of the treatment and the monitoring of different biological markers of infection (including viral load and the CD4 T-lymphocyte count).

The study was carried out under double-blinded conditions in two AP-HP (Paris Public Hospitals System) academic reference clinical centers at Hospital de la Pitié Salpêtrière and Hospital Cochin.

The results showed that VAC-3S was well tolerated, thus meeting the primary endpoint of the study. Full results of this study will be presented at an international medical conference.

Professor Christine Katlama, in the Infectious and Tropical Diseases Department at Hôpital de la Pitié Salpêtrière and principal investigator for the study, stated: "These results are important insofar as the primary study endpoint has been achieved. A treatment regimen consisting of three injections of VAC-3S was thus well tolerated. This is a key stage in the clinical development of this immunotherapy, which will supplement the antiretroviral therapies that are currently available."

Professor Odile Launay, Coordinating Physician at the Cochin-Pasteur Vaccinology Clinical Investigation Center at Hôpital Cochin, and joint investigator for the study, added: "Observation of the safety of VAC-3S after three injections is very encouraging in terms of the future development prospects for this immunotherapy".

Dr Shahin Gharakhanian, acting Chief Medical Officer of InnaVirVax who is based in the Cambridge Innovation Center (Cambridge, Massachusetts, USA), went on: "We are looking forward to analyzing these results in detail in terms of the full set of endpoints.

We are also actively preparing the next stage, which will involve submission of an application for a Phase II clinical study that takes account of the regulatory requirements for our type of product. We are also in discussion with US and European experts, and thus are working closely with clinicians in major centers.

Joël Crouzet, CEO of InnaVirVax concluded: "These clinical data obtained with the candidate immunotherapy VAC-3S are encouraging. The promising findings we are revealing today confirm the validity of our strategy, which aims to protect a patient's immune system. VAC-3S may therefore constitute an innovation for HIV patients by preserving their immune system".

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

InnaVirVax Strengthens Patent Protection of VAC-3S Immunotherapy
The Company reaches a new stage of development with the filing of a new European patent application for VAC-3S aimed at protecting the immune system of patients infected with HIV-1.
Wednesday, December 26, 2012
InnaVirVax Announces the Launch of the First Clinical Trial on VAC-3S
This trial is supported by a grant from the “OSEO” French Innovation Agency.
Tuesday, March 06, 2012
Scientific News
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
Developing Drug Resistance may be a Matter of Diversity for Tuberculosis
Researchers have probed the bacteria that causes tuberculosis, Mycobacterium tuberculosis, to learn more about how individual bacterial cells change and adapt while in the human body.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
Some Gut Microbes May Be Keystones of Health
University of Oregon scientists have found that strength in numbers doesn’t hold true for microbes in the intestines. A minority population of the right type might hold the key to regulating good health.
Essential Component of Antiviral Defense Identified
Infectious disease researchers at the University of Georgia have identified a signaling protein critical for host defense against influenza infection.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Is Allergy the Price We Pay for Our Immunity to Parasites?
New findings help demonstrate the evolutionary basis for allergy.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos